Dainippon's Latuda gets approval in Canada to treat bipolar depression - 1 views
-
Alex Parker on 04 Apr 14Dainippon Sumitomo Pharma (DSP) has received approval from Health Canada for use of Latuda (lurasidone HCl) as monotherapy or as adjunctive therapy with lithium or valproate to treat depressive episodes associated with bipolar I disorder.